5α,17β-dihydroxy-5α-androstan-3-one | 49644-01-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α,17β-dihydroxy-5α-androstan-3-one
• 英文别名: (5R,8S,9S,10R,13S,14S,17S)-5,17-dihydroxy-10,13-dimethyl-2,4,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 49644-01-1
• 化学式: C₁₉H₃₀O₃
• 分子量: 306.445
• InChiKey: OOFHIFZCMQKEBH-UYYZUGKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  17β-hydroxy-4α,5-epoxy-5α-androstan-3-one 在 naphthalen-1-yl-lithium 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以87%的产率得到5α,17β-dihydroxy-5α-androstan-3-one
  参考文献：
  名称：

  Lithium naphthalenide induced reductive cleavage of α,β-epoxy ketones: an efficient procedure for the preparation of β-hydroxy ketones

  摘要：

  萘基锂化合物作为一种温和且高效的试剂，能够有效地切割α,β-环氧酮，从而以良好的产率生成相应的β-羟基酮。

  DOI：

  10.1039/a904646a

文献信息

• Crabb, Trevor A.; Ratcliffe, Norman M., Journal of Chemical Research, Miniprint, 1986, # 2, p. 650 - 669
  作者：Crabb, Trevor A.、Ratcliffe, Norman M.

  DOI：——

  日期：——
• ORAL PHARMACEUTICAL COMPOSITION COMPRISING 15-HYDROXYTESTOSTERONE AND ITS ANALOGUES
  申请人：Pantarhei Bioscience B.V.

  公开号：EP1551415B1

  公开（公告）日：2009-12-23
• Pharmaceutical application of 15- or 16-substituted testosterone analogues
  申请人：Bunschoten Johannes Evert

  公开号：US20060122158A1

  公开（公告）日：2006-06-08

  The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 μg of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term “15-hydroxytestosterones” encompasses both 15β-hydroxytestosterone (15α, 17β-dihydroxy-4-androsten-3-one) and 15β-hydroxytestosterone (15β, 17β-dihydroxy-4-androsten-3-one). Similarly, the term “16-hydroxytestosterones” encompasses both 16α-hydroxytestosterone hydroxytestosterone (16α, 17β-dihydroxy-4-androsten-3-one) and 16α-hydroxytestosterone (16β, 17β-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.
• SINGLE MOLECULE-FORMAT BIOLUMINESCENT PROBE
  申请人：Umezawa Yoshio

  公开号：US20100273150A1

  公开（公告）日：2010-10-28

  This application aims to provide a single molecule-format probe for detecting a target-specific ligand easily and accurately as an index of the presence or absence of a signal. The invention is a single molecule-format bioluminescent probe for detecting a target-specific ligand in a living cell, which comprises, a ligand-binding molecule of which conformation is changed upon binding to the ligand, and an N-terminal polypeptide (N-LE) and a C-terminal polypeptide (C-LE) of a luminescent enzyme (LE), which are linked to each end of the ligand-binding molecule, respectively, wherein the N-LE and the C-LE self-complement to generate a luminescent signal only upon binding of the ligand to the ligand-binding molecule. The ligand-binding molecule is a fusion molecule carrying a ligand-binding domain (LBD) and an LBD-interacting domain or peptide that interacts with the LBD upon binding of the ligand to the LBD.
• US7943602B2
  申请人：——

  公开号：US7943602B2

  公开（公告）日：2011-05-17